SARS-CoV2 (COVID-19) Seroepidemiological Transplanted Subjects (Kidney, Kidney-pancreas, Pancreas, Langerhans Islets)

NCT ID: NCT04487197

Last Updated: 2021-02-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

282 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-15

Study Completion Date

2021-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate SARS-CoV2 infection and the degree of immunity possibly developed in transplanted population using the Luciferase Immuno Precipitation System (LIPS) test.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Transplant Pancreatic Transplat Pancreatic Islets Langerhans

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

* Adult patients (age ≥ 18 years),
* kidney or pancreas or pancreatic islets transplantation
* transplanted patients (period: 01.01.2020 to 30.06.2020)

blood sample for seroepidemiological investigation

Intervention Type PROCEDURE

blood sample for seroepidemiological investigation

Cohort 2

* Adult patients (age ≥ 18 years),
* kidney or pancreas or pancreatic islets transplantation
* Transplanted patients in follow-up since 01.01.2020 or trasplanted patients after 30.06.2020.

blood sample for seroepidemiological investigation

Intervention Type PROCEDURE

blood sample for seroepidemiological investigation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sample for seroepidemiological investigation

blood sample for seroepidemiological investigation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (age ≥ 18 years),
* Kidney or pancreas or pancreatic islets transplantation
* Transplanted patients (period: 01.01.2020 to 30.06.2020)
* Informed Consent signed


* Adult patients (age ≥ 18 years),
* Kidney or pancreas or pancreatic islets transplantation
* transplanted patients in follow-up since 01.01.2020 or trasplanted patients after 30.06.2020.
* Informed Consent signed

Exclusion Criteria

Symptomatology such as fever\> 37.5, and / or cough and / or respiratory distress and / or diarrhea / vomiting in 14 days prior to collection of blood sample
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Antonio Secchi

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Antonio Secchi

MD

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IRCCS San Raffaele

Milan, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COVID-SIERO TRAPIANTI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety of Rifaximin in Treating MAFLD
NCT07185932 RECRUITING EARLY_PHASE1